» Articles » PMID: 25231130

Gleason Drift in the NIHR ProtecT Study

Abstract

Aims: There is increasing evidence of Gleason score (GS) drift in prostatic core biopsies during the last two decades. The ProtecT study is a randomized controlled study and provides an excellent cohort to study the effect of time, prostate-specific antigen (PSA) level, perineural invasion, tumour length and age on GS.

Methods And Results: The ProtecT study recruited men in the United Kingdom between 1999 and 2010. The Gleason scores were grouped into four categories ≤ 3 + 3, 3 + 4, 4 + 3 and ≥ 4 + 4 for analysis. Data from England between 2000 and 2012 were also available. A total of 3282 biopsies containing cancer were analysed. For each year of the ProtecT study, the odds of being diagnosed with a higher GS category increased by 4.9%. Higher GS was also associated with perineural invasion, increasing tumour length, age and PSA level. While biopsy GS from England was incomplete, it also showed a marked decrease in GS five and six tumours during the same period.

Conclusion: There was GS drift from 3 + 3 to 3 + 4 with time in the ProtecT study, but there appeared to be no significant change in percentage of GS 4 + 3 or higher. This drift was less dramatic when compared to GS in the rest of England.

Citing Articles

Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.

Hamdy F, Donovan J, Athene Lane J, Mason M, Metcalfe C, Holding P Health Technol Assess. 2020; 24(37):1-176.

PMID: 32773013 PMC: 7443739. DOI: 10.3310/hta24370.


The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression.

Bryant R, Oxley J, Young G, Lane J, Metcalfe C, Davis M BJU Int. 2020; 125(4):506-514.

PMID: 31900963 PMC: 7187290. DOI: 10.1111/bju.14987.


The percentage of high-grade prostatic adenocarcinoma in prostate biopsies significantly improves on Grade Groups in the prediction of prostate cancer death.

Berney D, Beltran L, Sandu H, Soosay G, Moller H, Scardino P Histopathology. 2019; 75(4):589-597.

PMID: 31032963 PMC: 6790619. DOI: 10.1111/his.13888.


Histopathologic False-positive Diagnoses of Prostate Cancer in the Age of Immunohistochemistry.

Beltran L, Ahmad A, Sandu H, Kudahetti S, Soosay G, Moller H Am J Surg Pathol. 2018; 43(3):361-368.

PMID: 30531531 PMC: 6375390. DOI: 10.1097/PAS.0000000000001202.


Quality assurance guidance for scoring and reporting for pathologists and laboratories undertaking clinical trial work.

Robinson M, James J, Thomas G, West N, Jones L, Lee J J Pathol Clin Res. 2018; 5(2):91-99.

PMID: 30407751 PMC: 6463860. DOI: 10.1002/cjp2.121.